Literature DB >> 10469922

Size distribution measurements of metered dose inhalers using Andersen Mark II cascade impactors.

S W Stein1.   

Abstract

The performance of Andersen Mark II impactors was investigated theoretically and experimentally. Theoretical calculations were made to assess the impact that differences in jet diameters among Mark II impactors have on size distribution measurements of metered dose inhalers (MDIs). A previous investigation indicated that the jet diameter for stages on Mark II impactors often do not conform to the manufacturer's specifications (Stein and Olson, 1997). For the calculations reported in this paper, only jet diameters that conform to the manufacturer's specifications were considered. The calculations indicate that large differences in the amount of drug collecting on a given stage should be expected among Mark II impactors sampling an identical aerosol-even for Mark II impactors that conform to the manufacturer's specifications. These calculations suggest that it is impractical to analyze size distribution data generated with cascade impactors, such as the Mark II, on a stage-by-stage basis. Experimental measurements of three MDI products were made using three different Andersen Mark II cascade impactors. Measurements of the same product were very consistent for a given impactor, but large differences were observed in measurements of the same product with different impactors. For measurements of QVAR HFA beclomethasone dipropionate MDIs using three Mark II impactors, the amount of drug that collected on Stage 6 ranged from 28.7 to 41.3% of the sampled mass depending on which impactor was used. The theoretical calculations and experimental measurements reported in this paper demonstrate that it is important to consider the limited precision of cascade impactors, such as the Andersen Mark II, when analyzing the size distribution measurements that they provide.

Entities:  

Mesh:

Year:  1999        PMID: 10469922     DOI: 10.1016/s0378-5173(99)00136-2

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography.

Authors:  Nicholas Mason-Smith; Daniel J Duke; Alan L Kastengren; Peter J Stewart; Daniela Traini; Paul M Young; Yang Chen; David A Lewis; Julio Soria; Daniel Edgington-Mitchell; Damon Honnery
Journal:  Pharm Res       Date:  2016-02-17       Impact factor: 4.200

Review 2.  Minimizing variability of cascade impaction measurements in inhalers and nebulizers.

Authors:  Matthew Bonam; David Christopher; David Cipolla; Brent Donovan; David Goodwin; Susan Holmes; Svetlana Lyapustina; Jolyon Mitchell; Steve Nichols; Gunilla Pettersson; Chris Quale; Nagaraja Rao; Dilraj Singh; Terrence Tougas; Mike Van Oort; Bernd Walther; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2008-02-28       Impact factor: 3.246

3.  Estimating the number of droplets and drug particles emitted from MDIs.

Authors:  Stephen W Stein
Journal:  AAPS PharmSciTech       Date:  2008-01-17       Impact factor: 3.246

Review 4.  Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices.

Authors:  Eric Derom; Romain A Pauwels
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Adhesion of powders for inhalation: an evaluation of drug detachment from surfaces following deposition from aerosol streams.

Authors:  Martyn J Clarke; Joanne Peart; Stefano Cagnani; Peter R Byron
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

6.  Tuning aerosol particle size distribution of metered dose inhalers using cosolvents and surfactants.

Authors:  Imran Y Saleem; Hugh D C Smyth
Journal:  Biomed Res Int       Date:  2013-07-24       Impact factor: 3.411

7.  Water Uptake by Evaporating pMDI Aerosol Prior to Inhalation Affects Both Regional and Total Deposition in the Respiratory System.

Authors:  Victoria Legh-Land; Allen E Haddrell; David Lewis; Darragh Murnane; Jonathan P Reid
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.